Although it appears that chronic RT beneficially alters factors in the IGF axis to reduce bioavailable IGF-1, larger RCTs are needed to ascertain the clinical impact of these results on the progression of prostate cancer. The gene discussed is IGF1; the disease is prostate cancer.